Comparison between Neochem Bio IPO and Value 360 Communications IPO.
Neochem Bio IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Value 360 Communications IPO is a SME Bookbuilding proposed to list at NSE SME.
| Neochem Bio IPO | Value 360 Communications IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | NSE SME | NSE SME |
| Lead Managers | Vivro Financial Services Pvt.Ltd. | Holani Consultants Pvt.Ltd. |
| Registrar | MUFG Intime India Pvt.Ltd. | Kfin Technologies Ltd. |
| Market Maker | Rikhav Securities Ltd. | |
| DRHP | DRHP  | DRHP |
| RHP | RHP | |
| Final Prospectus | Final Prospectus | |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL |
The total issue size of Neochem Bio IPO is up to ₹42.69 Cr whereas the issue size of the Value 360 Communications IPO is up to ₹0.00 Cr. The final issue price of Neochem Bio IPO is ₹98.00 per share and of Value 360 Communications IPO is .
| Neochem Bio IPO | Value 360 Communications IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹93.00 per share | |
| Issue Price (Upper) | ₹98.00 per share | |
| Issue Price (Final) | ₹98.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 1200 shares | |
| Fresh Issue Size | 43,56,000 shares | 38,30,000 shares |
| Fresh Issue Size (Amount) | up to ₹42.69 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 0 shares | 4,25,000 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 43,56,000 shares | 38,30,000 shares |
| Issue Size Total (Amount) | up to ₹42.69 Cr | up to ₹0.00 Cr |
Neochem Bio IPO opens on Dec 02, 2025, while Value 360 Communications IPO opens on . The closing date of Neochem Bio IPO and Value 360 Communications IPO is Dec 04, 2025, and , respectively.
| Neochem Bio IPO | Value 360 Communications IPO | |
|---|---|---|
| Anchor Bid Date | Dec 01, 2025 | |
| Issue Open | Dec 02, 2025 | |
| Issue Close | Dec 04, 2025 | |
| Basis Of Allotment (Tentative) | Dec 05, 2025 | |
| Initiation of Refunds (Tentative) | Dec 08, 2025 | |
| Credit of Share (Tentative) | Dec 08, 2025 | |
| Listing date (Tentative) | Dec 09, 2025 | |
| Anchor Lockin End date 1 | Jan 04, 2026 | |
| Anchor Lockin End date 2 | Mar 05, 2026 |
Neochem Bio IPO P/E ratio is 15.85, as compared to Value 360 Communications IPO P/E ratio of .
| Neochem Bio IPO | Value 360 Communications IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)Neochem Bio Solutions Ltd.'s revenue increased by 39% and profit after tax (PAT) rose by 330% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 91.12 | 81.56 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 66.7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 15.85 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹167.78 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 48.82% | 35.74% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 41.67% | 37.18% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.80 | 1.26 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹6.18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 48.82% | 35.74% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Neochem Bio IPO Retail Individual Investors (RII) are offered 15,26,400 shares while in Value 360 Communications IPO retail investors are offered 15,26,400 shares. Qualified Institutional Buyers (QIB) are offered 8,71,200 shares in Neochem Bio IPO and 0 shares in Value 360 Communications IPO.
| Neochem Bio IPO | Value 360 Communications IPO | |
|---|---|---|
| Anchor Investor Reservation | 13,03,200 shares | 0 shares |
| Market Maker Reservation | 2,32,800 shares | 0 shares |
| QIB | 8,71,200 shares | 0 shares |
| NII | 6,55,200 shares | 0 shares |
| RII | 15,26,400 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 43,56,000 shares | 0 shares |
Neochem Bio IPO subscribed 15.52x in total, whereas Value 360 Communications IPO subscribed .
| Neochem Bio IPO | Value 360 Communications IPO | |
|---|---|---|
| QIB (times) | 21.97x | |
| NII (times) | 21.15x | |
| Big NII (times) | 25.78x | |
| Small NII (times) | 11.88x | |
| RII (times) | 9.42x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 15.52x |
